Silvina Natalini Martínez, Rafael Ramos, Jorge Navarro-Perez, Maria Jesus Lopez, Maria del Mar Vazquez, Jose Molto, Patricia Munoz, Jose M Echave, Jose R Arribas, Melchor Alvarez, Eunate Arana-Arri, Jordi Calls, Susana Otero-Romero, Francesco Scaglione, Laia Bernad, Raúl Pérez-Caballero, Julia G Prado, Ignasi Esteban, Elena Aurrecoechea, Roc Pomarol, Montserrat Plana, Alex Soriano

In this phase III, open label, single arm, multicenter clinical study, we report safety, tolerability and immunogenicity of PHH-1V as a booster dose in subjects primary vaccinated against COVID-19 with the BNT162b2, mRNA-1273, ChAdOx1-S, or Ad26.COV2.S vaccines, with or without previous COVID-19 infection. A total of 2661 subjects were included in this study and vaccinated with the PHH-1V vaccine.